Vaccine experts said the memo was irresponsible and omits key details about how officials arrived at the conclusion.
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast-track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback